And the FDA has approved Amgen’s Uplizna for adults with antibody-positive generalized myasthenia gravis, adding a ...

Explore how expanding clinical trials into community and nontraditional sites, simplifying protocols, and leveraging AI can ...

See how combining human oversight with AI insights improves protocol authorship, site selection, and monitoring strategies, ...

New data show that applying AI to the migration of translated COAs into eCOA platforms can meaningfully reduce errors, accelerate localization workflows, and support broader global patient ...

In today’s ACT Brief, we highlight new insights from McKinsey on where AI can meaningfully accelerate clinical development, break down the emerging design and regulatory forces reshaping obesity drug ...

In today’s ACT Brief, we break down FDA’s new superiority requirement reshaping CAR-T development, examine Pfizer’s global ...

Explore how AI can optimize study design, speed patient recruitment, and streamline operational workflows to shorten ...

As highly effective anti-obesity therapies emerge and regulatory expectations evolve, sponsors are adopting innovative trial designs, addressing long-term weight maintenance, monitoring lean mass ...

As highly effective anti-obesity therapies emerge and regulatory expectations evolve, sponsors are adopting innovative trial designs, addressing long-term weight maintenance, monitoring lean mass ...

In today’s ACT Brief, we explore how stronger vendor–sponsor governance is speeding eCOA study startup, hear from AMR ...

As highly effective anti-obesity therapies emerge and regulatory expectations evolve, sponsors are adopting innovative trial designs, addressing long-term weight maintenance, monitoring lean mass ...

For industry-sponsored trials in autoimmune inflammation therapeutic areas, the dominating indications include atopic ...